Immunomodulatory effects of VEGF: Clinical implications of VEGF-targeted therapy in human cancer

Cancer Biology and Therapy

Volumn 9, Issue 9, 2010, Pages 694-698

  Vitale, Giovanni ^a,b   Dicitore, Alessandra ^b   Gentilini, Davide ^b   Cavagnini, Francesco ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Bevacizumab; Immune system; Infection; Sepsis; VEGF; VEGF targeted therapy

Indexed keywords

ANGIOPOIETIN 1; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BEVACIZUMAB; BEVACIZUMAB PLUS CARBOPLATIN; CISPLATIN; ETOPOSIDE; PACLITAXEL; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

CANCER CHEMOTHERAPY; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; FEBRILE NEUTROPENIA; HUMAN; IMMUNOMODULATION; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; NEUTROPENIA; NEUTROPHIL; NOTE; NUCLEAR MAGNETIC RESONANCE; PNEUMONIA; THROMBOCYTE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; FEVER; INFECTION RISK; PROTEIN FUNCTION; TREATMENT RESPONSE; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; NEOPLASM; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOMODULATION; NEOPLASMS; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953693353     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.9.11691     Document Type: Note

References (29)

1. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219:983-5.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438:932-6.
3. Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76.
4. De Falco S, Gigante B, Persico MG. Structure and function of placental growth factor. Trends Cardiovac Med 2002; 12:241-6. (Pubitemid 35286760)
5. Roskoski RJ. VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun 2008; 375:287-91.
6. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005; 438:946-53.
7. de Paulis A, Prevete N, Fiorentino I, Rossi FW, Staibano S, Montuori N, et al. Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. J Immunol 2006; 177:7322-31.
8. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling in control of vascular function. Nat Rev Mol Cell Biol 2006; 7:359-71.
9. Reinders ME, Sho M, Izawa A, Wang P, Mukhopadhyay D, Koss KE, et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 2003; 112:655-65. (Pubitemid 38063723)
10. Ancelin M, Chollet-Martin S, Herve MA, Legrand C, El Benna J, Perrot-Applanat M. Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism. Lab Invest 2004; 84:502-12. (Pubitemid 41656478)
11. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87:3336-43.
12. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996; 271:17629-34. (Pubitemid 26250731)
13. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998; 95:9349-54. (Pubitemid 28506234)
14. Larrivee B, Lane DR, Pollet I, Olive PL, Humphries RK, Karsan A. Vascular endothelial growth factor receptor-2 induces survival of hematopoietic progenitor cells. J Biol Chem 2003; 278:22006-13. (Pubitemid 36792609)
15. Larrivée B, Pollet I, Karsan A. Activation of vascular endothelial growth factor receptor-2 in bone marrow leads to accumulation of myeloid cells: role of granulocyte-macrophage colony-stimulating factor. J Immunol 2005; 175:3015-24. (Pubitemid 41170520)
16. Ohki Y, Heissig B, Yayoi Sato Y, Akiyama H, Zhu Z, Hicklin DJ. Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils. FASEB J 2005; 19:2005-7.
17. Itaya H, Imaizumi T, Yoshida H, Koyama M, Suzuki S, Satoh K. Expression of vascular endothelial growth factor in human monocyte/macrophage stimulated with lipopolysaccharide. Thromb Haemost 2001; 85:171-6.
18. Sato F, Imaizumi T, Sashinami H, Yoshida H, Kusumi T, Mori F, et al. Upregulation of vascular endothelial growth factor by heat-killed Listeria monocytogenes in macrophages. Biochem Biophys Res Commun 2007; 354:608-12.
19. Hayashi K, Hooper LC, Detrick B, Hooks JJ. HSV immune complex (HSV-IgG: IC) and HSV-DNA elicit the production of angiogenic factor VEGF and MMP-9. Arch Virol 2009; 154:219-26.
20. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappaB activation in hemopoietic progenitor cells. J Immunol 1998; 160:1224-32.
21. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92:4150-66.
22. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166:678-89.
23. Shin JY, Yoon IH, Kim JS, Kim B, Par GC. Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells. Cell Immunol 2009; 256:72-8.
24. Osada T, Chong G, Tansik R, Hong T, Spector N, Kumar R, et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008; 57:1115-24.
25. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8:579-91.
26. Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, et al. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic, and anti-tumor activity of bevacizumab in advanced non-small-cell-lung cancer patients. Cancer Biol Ther 2010.
27. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (AVASTIN) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007; 12:713-8.
28. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008; 26:5254-60.
29. Lieuw-a-Fa M, Peringa J, Leeksma O, Terpstra W. Sepsis from liver abscesses in metastatic colorectal carcinoma after chemoimmunotherapy. J Clin Oncol 2008; 26:1381-2.